US FDA Issues Four Observations to Aurobindo Pharma Subsidiary's Facility in Hyderabad

The U.S. Food and Drug Administration (FDA) inspected Unit I of Eugia Pharma Specialities, a wholly owned subsidiary of Aurobindo Pharma near Hyderabad, from February 16 to 27, 2026, issuing four observations. This follows earlier FDA observations at two other Aurobindo-related facilities in February. Aurobindo Pharma stated these observations have no financial or operational impact and that it will respond to the FDA within the required timelines.